Age-Related Macular Degeneration
Q&A: Look for signs of AMD even in those without family history
Age-related macular degeneration can occur even in patients without a family history, so clinicians must be aware of early warning signs of the disease, according to Deborah Ferrington, PhD.
PulseSight Therapeutics launches with focus on non-viral gene therapies
PulseSight Therapeutics, which is developing non-viral gene therapies for retinal diseases, has launched with seed financing from Pureos Bioventures and ND Capital, according to a press release.
Ocugen completes dosing of first cohort in trial of gene therapy for Stargardt disease
Biotechnology company Ocugen announced that dosing is complete in the first cohort of its phase 1/2 GARDian clinical trial of OCU410ST, a modifier gene therapy candidate for treatment of Stargardt disease.
Opthea appoints Arshad M. Khanani as chief medical advisor
Arshad M. Khanani, MD, MA, FASRS, a renowned retina specialist and clinical researcher, has been appointed as chief medical advisor of Opthea Limited, according to a press release.
Treatment with acetylcholinesterase inhibitors for Alzheimer’s may reduce risk for AMD
Acetylcholinesterase inhibitors used to treat Alzheimer’s disease may also reduce the risk for developing age-related macular degeneration, according to a cohort study of older veterans published in JAMA Ophthalmology.
Macular neovascularization changes persist in AMD, even with long-term anti-VEGF therapy
Continuous growth of macular neovascularization size, as well as development of outer retina atrophy, was observed in neovascular age-related macular degeneration, even with frequent anti-VEGF treatment, according to research in PLoS One.
Six biomarkers predict AMD progression with greater certainty than ‘large drusen’ sign
Researchers have identified biomarkers that predict age-related macular degeneration progression as well as biomarkers associated with progression to geographic atrophy and neovascularization, according to a review published in Ophthalmology Retina.
VIDEO: Specialist calls approval of Vabysmo an important advance in treatment of RVO
In this expert perspective from Hawaiian Eye 2024, Roger A. Goldberg, MD, MBA, discusses the significance of the approval of Vabysmo from Genentech for the treatment of retinal vein occlusion.
What are the benefits and challenges of introducing AI-based tools in clinical practice?
The Notal OCT Analyzer is the AI segmentation algorithm that analyzes each of the daily OCT scans obtained by patients as part of a neovascular age-related macular degeneration remote-monitoring paradigm.
Ophthalmology on the brink of digital innovation in AI, machine learning
Common sight-threatening retinal diseases seen by all comprehensive ophthalmologists include wet age-related macular degeneration, geographic atrophy and diabetic macular edema.